Targeting mast cell activation alleviates anti-MHC I antibody and LPS-induced TRALI in mice by pharmacologically blocking the TLR3 and MAPK pathway
Open Access
- 24 September 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117456
Abstract
No abstract availableKeywords
Funding Information
- Fujian Provincial Department of Science and Technology (2023Y9339)
- Fujian Provincial Health Technology Project (2023CXA006)
- Natural Science Foundation of Sichuan Province (2023NSFSC1456)
- National Natural Science Foundation of China (82471278)
- National Natural Science Foundation of China (82171186)
This publication has 52 references indexed in Scilit:
- Comprehensive review of potential drugs with anti-pulmonary fibrosis propertiesBiomedicine & Pharmacotherapy, 2024
- Homeostatic chemokines as putative therapeutic targets in idiopathic pulmonary fibrosisTrends in Immunology, 2023
- GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAACell, 2022
- Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasationImmunity, 2021
- Transfusion in the mechanically ventilated patientIntensive Care Medicine, 2020
- Mast cells as effector cells of innate immunity and regulators of adaptive immunityImmunology Letters, 2016
- Increased activation of the transcription factor c-Jun by MAP kinases in monocytes of multiple trauma patients is associated with adverse outcome and mass transfusionJournal of Surgical Research, 2012
- Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleedingIntensive Care Medicine, 2010
- The role of the mast cell in the pathophysiology of asthmaJournal of Allergy and Clinical Immunology, 2006
- Transfusion-Related Acute Lung InjuryJAMA, 2002